FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247280175> ?p ?o ?g. }

• W4247280175 endingPage "e234" @default.
• W4247280175 startingPage "e234" @default.
• W4247280175 abstract "We thank Michael Balkin for his interest in our article.1Kawahigashi T Kawabe T Iijima H et al.Beware of perianal pain: Fournier gangrene.Am J Med. 2020; 133: 924-925Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar He made an important point about our case: The use of sodium glucose cotransporter-2 (SGLT2) inhibitors may be associated with the development of Fournier gangrene.2Stover KR Hugh E Sherman JJ Malinowski SS et al.Infectious complications of newer agents in the fight against diabetes.Nurse Pract. 2020; 45: 17-24Crossref Scopus (1) Google Scholar It is worthwhile to mention that diabetes is one of the most common comorbid risk factors for Fournier gangrene and the use of SGLT2 inhibitors for type 2 diabetes mellitus is increasing each year because of the significant cardiovascular benefit of SGLT2 inhibitors in people with type 2 diabetes.3Zou CY Liu XK Sang YQ Wang B Liang J Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis.Medicine (Baltimore). 2019; 98: e18245Crossref Scopus (22) Google Scholar In August 2018, the Food and Drug Administration (FDA) issued a warning regarding the occurrence of Fournier gangrene. A recent review of the Food and Drug Administration and case reports identified 55 cases of Fournier gangrene among patients receiving SGLT2 inhibitors between 2013 and 2019, compared with 19 cases among patients receiving all other antihyperglycemics between 1984 and 2019.1Kawahigashi T Kawabe T Iijima H et al.Beware of perianal pain: Fournier gangrene.Am J Med. 2020; 133: 924-925Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar Fortunately, our patient did not receive an SGLT2 inhibitor; instead, he was treated with teneligliptin hydrobromide hydrate, a dipeptidyl peptidase 4 (DPP-4) inhibitor. Although his type 2 diabetes mellitus was well controlled by the DPP-4 inhibitor (his hemoglobin A1c on admission was 6.9%), his Fournier gangrene would be associated with type 2 diabetes mellitus. DPP-4 inhibitors may pose a lower risk for adverse events such as urinary and urogenital tract infections than do SGLT2 inhibitors. However, further examinations are needed because some previous reports demonstrate that the use of SGLT2 inhibitors showed a similar risk of urinary tract infections among different second-line antidiabetic medications, DPP4 inhibitors, and glucagon-like peptide 1 agonists.4Dave CV Schneeweiss S Kim D et al.Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study.Ann Intern Med. 2019; 171: 248-256Crossref Scopus (51) Google Scholar In our case, SGLT-2 inhibitors did not contribute to Fournier gangrene; however, clinicians should be aware of the risks of SGLT-2 inhibitors in patients with comorbid risk factors for Fournier gangrene. Be Vigilant About Perianal PainThe American Journal of MedicineVol. 134Issue 3PreviewThe Diagnostic Dilemma reported by Kawahigashi et al is particularly timely in view of the increasing use of sodium glucose cotransporter 2 (SGLT2) inhibitors for diabetes and heart failure.1,2 Many of us are learning for the first time about Fournier gangrene and its relationship to SGLT2 inhibitors.3 We have now become more vigilant about questioning and evaluating our diabetic patients for perianal symptoms. Although there would appear to be no relationship to medication usage and the development of an abscess in what the authors described as a long-standing mass, given the evolving knowledge of Fournier gangrene we must be explicitly informed as to whether the patient was exposed to an SGLT2 inhibitor. Full-Text PDF" @default.
• W4247280175 created "2022-05-12" @default.
• W4247280175 creator A5006651214 @default.
• W4247280175 creator A5046435707 @default.
• W4247280175 date "2021-03-01" @default.
• W4247280175 modified "2023-10-14" @default.
• W4247280175 title "The Reply" @default.
• W4247280175 cites W2966426030 @default.
• W4247280175 cites W2992022999 @default.
• W4247280175 cites W3000267771 @default.
• W4247280175 cites W3094490846 @default.
• W4247280175 doi "https://doi.org/10.1016/j.amjmed.2020.11.005" @default.
• W4247280175 hasPublicationYear "2021" @default.
• W4247280175 type Work @default.
• W4247280175 citedByCount "0" @default.
• W4247280175 crossrefType "journal-article" @default.
• W4247280175 hasAuthorship W4247280175A5006651214 @default.
• W4247280175 hasAuthorship W4247280175A5046435707 @default.
• W4247280175 hasBestOaLocation W42472801751 @default.
• W4247280175 hasConcept C126322002 @default.
• W4247280175 hasConcept C134018914 @default.
• W4247280175 hasConcept C141071460 @default.
• W4247280175 hasConcept C16005928 @default.
• W4247280175 hasConcept C17744445 @default.
• W4247280175 hasConcept C199539241 @default.
• W4247280175 hasConcept C2776626339 @default.
• W4247280175 hasConcept C2777180221 @default.
• W4247280175 hasConcept C2779473830 @default.
• W4247280175 hasConcept C3018890749 @default.
• W4247280175 hasConcept C555293320 @default.
• W4247280175 hasConcept C61434518 @default.
• W4247280175 hasConcept C71924100 @default.
• W4247280175 hasConcept C83867959 @default.
• W4247280175 hasConcept C98274493 @default.
• W4247280175 hasConceptScore W4247280175C126322002 @default.
• W4247280175 hasConceptScore W4247280175C134018914 @default.
• W4247280175 hasConceptScore W4247280175C141071460 @default.
• W4247280175 hasConceptScore W4247280175C16005928 @default.
• W4247280175 hasConceptScore W4247280175C17744445 @default.
• W4247280175 hasConceptScore W4247280175C199539241 @default.
• W4247280175 hasConceptScore W4247280175C2776626339 @default.
• W4247280175 hasConceptScore W4247280175C2777180221 @default.
• W4247280175 hasConceptScore W4247280175C2779473830 @default.
• W4247280175 hasConceptScore W4247280175C3018890749 @default.
• W4247280175 hasConceptScore W4247280175C555293320 @default.
• W4247280175 hasConceptScore W4247280175C61434518 @default.
• W4247280175 hasConceptScore W4247280175C71924100 @default.
• W4247280175 hasConceptScore W4247280175C83867959 @default.
• W4247280175 hasConceptScore W4247280175C98274493 @default.
• W4247280175 hasIssue "3" @default.
• W4247280175 hasLocation W42472801751 @default.
• W4247280175 hasOpenAccess W4247280175 @default.
• W4247280175 hasPrimaryLocation W42472801751 @default.
• W4247280175 hasRelatedWork W1980857487 @default.
• W4247280175 hasRelatedWork W1998503926 @default.
• W4247280175 hasRelatedWork W2002120878 @default.
• W4247280175 hasRelatedWork W2047967234 @default.
• W4247280175 hasRelatedWork W2383009242 @default.
• W4247280175 hasRelatedWork W2383725167 @default.
• W4247280175 hasRelatedWork W2439875401 @default.
• W4247280175 hasRelatedWork W2900523252 @default.
• W4247280175 hasRelatedWork W3014961299 @default.
• W4247280175 hasRelatedWork W4281774296 @default.
• W4247280175 hasVolume "134" @default.
• W4247280175 isParatext "false" @default.
• W4247280175 isRetracted "false" @default.
• W4247280175 workType "article" @default.